Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI.
Richter J, Lübking A, Söderlund S, Lotfi K, Markevärn B, Själander A, Stenke L, Deneberg S, Ahlstrand E, Myhr-Eriksson K, Panayiotidis P, Gedde-Dahl T, Žáčková D, Mayer J, Olsson-Strömberg U, Mahon FX, Saussele S, Hjorth-Hansen H, Koskenvesa P. Richter J, et al. Among authors: ahlstrand e. Leukemia. 2021 Aug;35(8):2416-2418. doi: 10.1038/s41375-021-01173-w. Epub 2021 Feb 15. Leukemia. 2021. PMID: 33589755 Free PMC article. No abstract available.
Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid Leukemia.
Löf L, Arngården L, Olsson-Strömberg U, Siart B, Jansson M, Dahlin JS, Thörn I, Christiansson L, Hermansson M, Larsson A, Ahlstrand E, Wålinder G, Söderberg O, Rosenquist R, Landegren U, Kamali-Moghaddam M. Löf L, et al. Among authors: ahlstrand e. Sci Rep. 2017 Apr 4;7(1):623. doi: 10.1038/s41598-017-00755-y. Sci Rep. 2017. PMID: 28377570 Free PMC article.
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Flygt H, Söderlund S, Richter J, Saussele S, Koskenvesa P, Stenke L, Mustjoki S, Dimitrijevic A, Stentoft J, Majeed W, Roy L, Wolf D, Dreimane A, Gjertsen BT, Gedde-Dahl T, Ahlstrand E, Markevärn B, Hjorth-Hansen H, Janssen J, Olsson-Strömberg U. Flygt H, et al. Among authors: ahlstrand e. Leukemia. 2024 Apr;38(4):781-787. doi: 10.1038/s41375-024-02145-6. Epub 2024 Jan 26. Leukemia. 2024. PMID: 38278960 Free PMC article.
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Flygt H, Söderlund S, Richter J, Saussele S, Koskenvesa P, Stenke L, Mustjoki S, Dimitrijevic A, Stentoft J, Majeed W, Roy L, Wolf D, Dreimane A, Gjertsen BT, Gedde-Dahl T, Ahlstrand E, Markevärn B, Hjorth-Hansen H, Janssen J, Olsson-Strömberg U. Flygt H, et al. Among authors: ahlstrand e. Leukemia. 2024 Apr;38(4):925. doi: 10.1038/s41375-024-02184-z. Leukemia. 2024. PMID: 38418611 Free PMC article. No abstract available.
Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.
Andersen CL, Bjørn ME, McMullin MF, Harrison C, Samuelsson J, Ejerblad E, Zweegman S, Fernandes S, Bareford D, Knapper S, Löfvenberg E, Linder O, Andreasson B, Ahlstrand E, Jensen MK, Bjerrum OW, Vestergaard H, Larsen H, Klausen TW, Mourits-Andersen T, Skov V, Thomassen M, Kruse T, Grønbæk K, Hasselbalch HC. Andersen CL, et al. Among authors: ahlstrand e. Leuk Res. 2014 Jul;38(7):816-21. doi: 10.1016/j.leukres.2014.04.002. Epub 2014 Apr 14. Leuk Res. 2014. PMID: 24836761 Clinical Trial.
A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.
Andersen CL, McMullin MF, Ejerblad E, Zweegman S, Harrison C, Fernandes S, Bareford D, Knapper S, Samuelsson J, Löfvenberg E, Linder O, Andreasson B, Ahlstrand E, Jensen MK, Bjerrum OW, Vestergaard H, Larsen H, Klausen TW, Mourits-Andersen T, Hasselbalch HC. Andersen CL, et al. Among authors: ahlstrand e. Br J Haematol. 2013 Aug;162(4):498-508. doi: 10.1111/bjh.12416. Epub 2013 Jun 11. Br J Haematol. 2013. PMID: 23758082 Free article. Clinical Trial.
Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group.
Birgegard G, Samuelsson J, Ahlstrand E, Ejerblad E, Enevold C, Ghanima W, Hasselbalch H, Nielsen CH, Knutsen H, Pedersen OB, Sørensen A, Andreasson B. Birgegard G, et al. Among authors: ahlstrand e. Eur J Haematol. 2019 Mar;102(3):235-240. doi: 10.1111/ejh.13198. Epub 2019 Jan 1. Eur J Haematol. 2019. PMID: 30472746
22 results